Skip to main content
Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinib
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinib
User login
Username
Password
Reset your password
Concept
Lead
score
Hepatocellular Carcinoma
1
1
Angiogenesis Inhibitors
0
0.63
Cancer
0
0.63
Humanized Monoclonal Antibody
0
0.63
Biologic Therapy
0
0.32
Specialty
Lead
score
Hematology-Oncology
1
1
Gastroenterology
0
1
Edit Tags